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Abstract
Background:  Largely due to the lack of diagnostic reagents, the prevalence and clinical
presentation of cryptococcal meningitis in Tanzania is poorly understood. This in turn is limiting
the impact of increased fluconazole availability.
Methods: We evaluated a cohort of 149 consecutive HIV-infected adult inpatients presenting with
headache or altered mental status for clinical features, CD4 count, cryptococcal infection, and
outcome. Cryptococcal meningitis was diagnosed via India ink and latex agglutination assay of CSF
(n = 24 and 40 positive, respectively). Associations between cryptococcal meningitis and clinical
features were evaluated by t-test. The sensitivity, specificity, and positive likelihood ratio of such
features were determined.
Results: Cryptococcal meningitis was associated with confusion, social withdrawal, seizures, fever,
tachycardia, meningismus, oral candidiasis, and low Glasgow coma scales and CD4 count. CD4
count < 100/µl provided the highest sensitivity for the diagnosis (93%), coma (Glasgow coma scale
≤ 8) provided the highest specificity (84%), and the combination provided the highest positive
likelihood ratio (3.8). All cryptococcal meningitis patients were initiated on 800 milligrams of
fluconazole daily and 50% survived to discharge, however no clinical or laboratory findings
correlated with prognosis.
Conclusion: Cryptococcal meningitis is common among Tanzanian HIV inpatients presenting with
headache or altered mental status. Purely clinical features are insensitive for establishing the
diagnosis or prognosis. We advocate expanding laboratory capacity for cryptococcal antigen testing
to maximize survival.
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Background
Cryptococcus neoformans is a leading AIDS-associated
opportunistic infection and a major cause of adult menin-
gitis in studies from Central African Republic, South
Africa, Zambia, Zimbabwe [1-4]. In one report cryptococ-
cal meningitis (CM) was the first AIDS-defining illness in
88% of patients [5]. The scope of the problem is less clear
in Tanzania, where the literature is limited to one retro-
spective study that found Cryptococcus  in 7% of (175/
1144) CSF specimens [6]. A major reason for this lack of
clarity is the lack of diagnostic reagents. For instance the
Medical Stores Department, the main distributor of med-
ical reagents to Tanzania, does not procure either India
ink or cryptococcal antigen tests [7]. This leaves detection
in the unlikely hands of expensive private imports. The
need for accurate CM diagnosis is heightened by the
increased availability of therapeutics to many parts of
Africa, particularly fluconazole [8]. We therefore chose to
examine a large cohort of Tanzanian HIV inpatients with
central nervous system presentations to determine the
local rate of CM using CSF cryptococcal antigen testing as
the gold standard. We also sought to determine whether
particular clinical features could predict the diagnosis as a
stopgap measure until diagnostic reagents for CM become
more widely available.
Results
Prevalence and clinical features of cryptococcal meningitis 
in Kilimanjaro region
This study took place on the inpatient medical ward of
Kilimanjaro Christian Medical Centre, Moshi, Tanzania, a
tertiary referral hospital. One hundred forty nine consec-
utive inpatients met enrollment criteria of headache (n =
86), altered mental status (Glasgow coma scale < 14; n =
5), or both (n = 58). Cryptococcal meningitis was diag-
nosed in CSF in 24 (17%) patients by India ink stain and
in 40 (29%) by latex agglutination (P = 0.03 vs. India ink;
sensitivity of India ink vs. latex agglutination 60%, specif-
icity 100%). Several presenting features were statistically
associated with the diagnosis of CM, including confusion,
social withdrawal, seizures, fever, tachycardia, meningis-
mus, oral candidiasis, and low Glasgow coma scales and
CD4 count (Table 1). Spinal fluid indices were largely
undiscerning. CM patients had a higher average pleocyto-
sis (Table 1), however 50% of CM patients had an absence
or paucity of CSF cells (a poor prognostic sign [2,12]).
Additionally, 62% of the non-CM group had no CSF cells,
indicating that meningitis was uncommon in many such
patients with HIV and headache and/or altered mental
status.
Sensitivity and specificity of clinical features for the 
diagnosis
Although all patients received lumbar puncture and CSF
cryptococcal antigen testing in this study, such tests are
not always possible or available in Tanzania, and there-
fore we sought to evaluate whether clinical features alone
could strengthen the likelihood of CM. Each clinical vari-
able from Table 1 was examined for sensitivity and specif-
icity alone and in combination (Figure 1). The most
discriminating variables from Table 1 (social withdrawal,
history of confusion, objective fever, oral candidiasis,
coma, CD4 < 100/µl) gave the highest J scores (i.e., sensi-
tivity + specificity - 1; data not shown) and are labeled in
Figure 1. Notably, CD4 count < 100/µl provided the high-
est sensitivity (0.93, 95% CI 0.79 – 0.98; specificity 0.49)
while coma provided the highest specificity (0.84, 95% CI
0.76 – 0.90; sensitivity 0.37). Of any variable or combina-
tion, CD4 count < 100/µl plus coma provided the highest
J score, positive predictive value (0.58), and positive like-
lihood ratio (3.8, 95% CI 1.9 – 7.3). As expected, combin-
ing multiple clinical features, such as "confusion or fever
or oral candidiasis" or "confusion and fever and oral can-
didiasis" could further drive sensitivity or specificity,
respectively, but not both.
Outcome
At the time of this study fluconazole was freely available,
such that the physicians placed all patients with a positive
CSF cryptococcal antigen test on 800 milligrams flucona-
zole per day orally or per nasogastric tube. Antiretroviral
therapy (generally lamivudine, stavudine, and nevirap-
ine) was either initiated or continued. Fifty percent (n =
20) of CM patients recovered and survived to discharge.
CM was associated with mortality independent of CD4
count (18/37 CM patients with CD4 < 100/µl died vs. 15/
56 non-CM patients with CD4 < 100/µl, P < 0.05). India
ink positivity was not associated with a worse outcome
(10/24 India ink positive patients died vs. 10/16 India ink
negative CM patients; P = NS). Indeed, there was no statis-
tical association between CM mortality and any of the
clinical or laboratory indices measured (data not shown),
only trends towards higher rates of hypertension (6/20 vs.
1/19; P = 0.09), higher opening pressure (median 14.5 vs.
10; P = 0.10), and higher erythrocyte sedimentation rates
(median 106 vs. 78; P = 0.06) in the CM patients that
died.
Discussion
Our study shows that CM is common in northern Tanza-
nia, occurring in 27% of HIV patients presenting with
headache or AMS. The high rate is not surprising,
although the magnitude of the problem had not been
clear locally. Most reports on the severity of CM in Africa
have originated from the South [1-3,5], leading some to
question whether the disease is less common in the East
and West [13,14]. Our results suggest the burden is also
enormous in this region, similar to that seen in the Zim-
babwe study [2].BMC Infectious Diseases 2007, 7:39 http://www.biomedcentral.com/1471-2334/7/39
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The survival of our cohort was 50% to discharge. While
less than the >80% survival seen in developed countries
with the same 800 mg fluconazole regimen [15], our
patients had far advanced disease and coma rates, and
50% survival is better than many reports from Africa
[1,16,17]. Improved therapeutic regimens for CM are
clearly needed, and one wonders if any added benefit
would come from an additional agent such as flucytosine
as seen in Uganda [18].
However we would advocate that improvements in thera-
peutics must be wed to improvements in diagnostics
availability. During the time of study fluconazole was free
(made available thanks to the Pfizer Diflucan Partnership
Program), but this availability would have been aimless
without cryptococcal antigen detection. Unfortunately,
India ink exhibited a disappointing 60% sensitivity, worse
than a clinical determination based on low CD4 count
plus coma, therefore we are left advocating for increased
availability of cryptococcal antigen tests (including use on
serum [19]). As mentioned, the cryptococcal antigen test
is presently not available through local dispensaries or
Tanzania's Medical Stores Department, the country's
main supplier of essential medicines and reagents. For the
study tests were imported at a cost of $5.18 per test, admit-
tedly not practical for a country whose per capita health
Table 1: Historical, examination, and laboratory findings in patients with cryptococcal meningitis.
Cryptococcal meningitis (n = 40) Other (n = 109) P
Age (median, range) 41 (14–65) 37 (13–64) NS
Female sex 45% (18) 45% (49) NS
History
Subjective fever 83% (33) 62% (68) NS
Subjective wt loss 65% (26) 53% (58) NS
Confusion 73% (29) 45% (49) 0.003
Vomiting 48% (19) 31% (34) NS
Social withdrawal 43%(17) 18% (20) 0.004
Seizures 35% (14) 19% (21) 0.05
On antiretroviral therapy 18% (7) 24% (26) NS
Physical examination
Febrile (T >38.0°C) 73% (29) 47% (51) 0.006
Hypertensive (>140/90 mm Hg) 18% (7) 14% (15) NS
Tachycardia 60% (24) 39% (42) 0.03
Meningismus 43% (18) 23% (28) 0.02
Oral thrush 48% (19) 24% (26) 0.008
Temporal wasting 50% (20) 35% (38) NS
Abnormal GCS (≤ 14) 73% (29) 29% (32) <0.0001
Coma (GCS ≤ 8) 50% (20) 16% (17) <0.0001
Median GCS 8.5 15 <0.0001
Laboratory
Leukocytes × 103/µl (median) 6.4 ± 7.1 (5.4) 6.1 ± 5.6 (6)* NS
Lymphocytes × 103/µl (median) 2.0 ± 1.3 (1.7) 1.9 ± 1.2 (2.0) NS
CD4 count/µl (median) 49.5 ± 45.2 (39) 190.0 ± 216.4 (89) <0.0001
CD4 < 100/µl 93% (37) 51% (56) <0.0001
Haemoglobin g/dl (median) 23.2 ± 29.1 (11.1) 17.9 ± 20.6 (12)* NS
Platelets × 103/µl (median) 161 ± 88 (141) 179 ± 104 (163) NS
ESR (median) 87 ± 40 (93) 74 ± 39 (75) NS
CSF†
Pleocytosis % > 2/µl (n) 50% (20) 38% (41) NS
Leukocytes (#/µl)† 63 ± 90 14 ± 23 0.03
Lymphocytes‡ (%) 53 ± 40 37 ± 34 NS
Neutrophils‡ (%) 47 ± 40 60 ± 34 NS
CSF protein (g/L)† 1.2 ± 2.3 0.7 ± 0.7 NS
CSF glucose (mmol/L)† 2.4 ± 1.3 3.0 ± 1.2 NS
CSF opening pressure (mmHg) 14.2 ± 10.6 9.8 ± 8.6 0.02
Outcome
Survival to discharge 50% (20) 80% (87) 0.0008
Data shown are mean ± SD unless otherwise specified.
* no haemoglobin or leukocyte data from 1 other patient
† CSF cell counts, protein, glucose, and opening pressure results compare CM and only those other patients with meningitis, defined as CSF 
pleocytosis > 2/ml.
‡ CSF differential data available only from 12 CM and 11 non-CM patients.BMC Infectious Diseases 2007, 7:39 http://www.biomedcentral.com/1471-2334/7/39
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expenditure is $12 [20]. However even at this high price
per test, assuming fluconazole costs the present $0.97 per
100 mg in Tanzania (and will not always be donated), the
diagnostic vs. therapeutic cost per CM survivor remains
miniscule.
The finding that low CD4 count plus coma was a reason-
ably sensitive and specific feature for CM is unfortunate.
First, clearly it requires CD4 quantitation, which although
is presently more available in our region of Tanzania, is
also technically demanding and expensive. Secondly, the
finding of coma may provide high specificity but will
inherently miss earlier and better-prognosis presentations
[21]. Therefore while intuitively appealing to devise clini-
cal management algorithms in settings with limited labo-
ratory resources, we by no means advocate clinical
diagnosis for this entity and would simply emphasize that
the knowledge of CD4 < 100/µl plus coma in Tanzania
should prompt strong consideration of CM.
Given CM's high mortality in Africa it seems prudent to
examine preventive approaches instead of waiting until
patients have advanced disease. We would predict that flu-
conazole prophylaxis in Tanzanian patients with CD4 <
100/µl, although costly, would prevent mortality (in con-
trast to the American study [22]). Alternatively, periodic
screening of such patients with serum cryptococcal anti-
gen could be comparator approach, accepting that this
switches cost and infrastructure demands to the labora-
tory instead of the pharmacy.
There were a few final observations from our study. First,
all patients underwent lumbar puncture, and this showed
that many HIV patients with headache or altered mental
status do not have meningitis. In many resource-limited
settings where lumbar puncture is not performed due to
erratic availability of equipment, empiric antibiotics are
the norm, and our data would suggest this is often unnec-
essary and a waste of resources. Additionally, of the 149
admissions we document, 21% (24/113) of patients with
CD4 < 200/µl were already on antiretroviral therapy, a
starting point towards WHO and Global Fund goals.
Conclusion
Cryptococcal meningitis is common among Tanzanian
HIV inpatients presenting with headache or altered men-
tal status. Given the insensitivity of purely clinical features
for establishing the diagnosis or prognosis, we advocate
expanding laboratory capacity for cryptococcal antigen
testing to maximize survival.
Methods
Patients
Patients aged 13 – 65 were enrolled from the inpatient
medical ward of the Kilimanjaro Christian Medical Centre
(KCMC) from June 2005 – May 2006. Eligible patients
included 162 consecutive HIV-positive inpatients with
headache and/or altered mental status (Glasgow coma
scale < 14). Thirteen patients were excluded from evalua-
tion by lumbar puncture for concerns of papilloedema
(3), cranial nerve palsies (2), or focal motor deficits (8).
Informed consent for lumbar puncture was obtained from
all participants, the University of Virginia Human Investi-
gation Committee and the Kilimanjaro Christian Medical
Centre Ethics Committee reviewed and approved the
project, and all research was in compliance with the Hel-
sinki Declaration. Patient histories came from the patient
when possible else the patient's friends and/or family. All
therapies were ordered by the consultant physician. Chart
review demonstrated that all CM patients were initiated
on 800 mg fluconazole (Diflucan, Pfizer, New York, NY)
orally or per nasogastric tube for 2 weeks, followed by 400
mg orally for 4 weeks, followed by 200 mg orally thereaf-
ter. Of note, amphotericin B and flucytosine were not
available in Tanzania at the time of this study, nor are they
presently.
Laboratory
Cryptococcal infection was assayed in cerebrospinal fluid
by India ink testing (Becton Dickinson, Sparks, MD) and
Sensitivity and specificity of clinical features for the diagnosis  of Cryptococcal meningitis Figure 1
Sensitivity and specificity of clinical features for the 
diagnosis of Cryptococcal meningitis. The 95% confi-
dence intervals of sensitivity and specificity for the clinical 
features associated with CM from Table 1 were plotted. Sen-
sitivity and specificity for all possible combinations of clinical 
features were plotted as well. CSF India ink is shown for 
comparison. Diagonal line represents a Youden's J index of 0, 
such that tests to the left of the line are worthless (Youden's 
J ≤ 0) and tests to the far right are more worthwhile.
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cryptococcal antigen latex agglutination (Murex Crypto-
coccus Test, Remel, Lenexa, KS). CD4 count was measured
using the Coulter Manual CD4 Count kit (Beckman Coul-
ter, Hialeah, FL). Haematology assays on CSF were per-
formed at the KCMC Clinical laboratory with a Coulter
counter and by microscopy.
Statistics and diagnostic performance
Means and medians were compared using t test and
Mann-Whitney test, respectively. All P  values are two-
tailed. Data shown are mean ± SD unless otherwise indi-
cated. In accordance with STARD guidelines, the CSF cryp-
tococcal antigen assay was utilized as the gold-standard
test for the diagnosis of CM. Confidence intervals for pro-
portions (sensitivity and specificity) were calculated using
the Wilson score method [9]. Confidence intervals for
positive and negative likelihood ratios were calculated as
previously described [10]. The Youden's J index is used to
rate the overall performance of a test and is calculated by
(sensitivity + specificity - 1), where 0 is worthless and 1 is
perfect. The positive likelihood ratio (= true positive rate/
false positive rate) has been shown to be a superior
method to convey the diagnostic value of a positive test
result to clinicians [11].
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